Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Linagliptin (Primary) ; CD26 antigen inhibitors; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Jun 2019 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 15 Mar 2019 to 15 May 2019.
- 16 Apr 2019 Planned primary completion date changed from 15 Mar 2019 to 15 May 2019.